BIOCRYST PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOCRYST PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $25.19M | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $26.35M | Mar 12, 2018 |
| FY2017 | Dec 31, 2015 | $48.26M | Mar 12, 2018 |
| FY2016 | Dec 31, 2014 | $13.61M | Feb 27, 2017 |
| FY2015 | Dec 31, 2013 | $17.33M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $26.29M | Mar 2, 2015 |
| FY2013 | Dec 31, 2011 | $19.64M | Mar 10, 2014 |
| FY2012 | Dec 31, 2010 | $62.38M | Mar 11, 2013 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.89M | Mar 12, 2018 |
| FY2017 | Sep 30, 2017 | $8.76M | Mar 12, 2018 |
| FY2017 | Jun 30, 2017 | $3.10M | Mar 12, 2018 |
| FY2017 | Mar 31, 2017 | $9.44M | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $8.98M | Mar 12, 2018 |
| FY2017 | Sep 30, 2016 | $7.76M | Mar 12, 2018 |
| FY2017 | Jun 30, 2016 | $4.79M | Mar 12, 2018 |
| FY2017 | Mar 31, 2016 | $4.82M | Mar 12, 2018 |
| FY2016 | Dec 31, 2015 | $4.60M | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $10.99M | Feb 27, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.86M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($88.88M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($226.54M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($247.12M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($184.06M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | ($60.49M) | Mar 1, 2021 |
| FY2020 | Sep 30, 2020 | ($46.12M) | Mar 1, 2021 |
| FY2020 | Jun 30, 2020 | ($38.61M) | Mar 1, 2021 |
| FY2020 | Mar 31, 2020 | ($37.60M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | ($2.62M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.54M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($103.71M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($148.44M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($177.72M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($174.76M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($99.46M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($94.22M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($57.41M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($48.61M) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $174.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $216.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $253.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $208.81M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $122.96M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $107.07M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $84.89M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $66.96M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $61.01M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $266.35M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $214.07M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $159.37M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $118.82M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $67.93M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $37.12M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $29.51M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $13.93M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $11.25M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.37M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($52.02M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($95.14M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($161.85M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($142.16M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($135.11M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($89.58M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($92.57M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($41.14M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($53.44M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $343.0K | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $366.0K | Mar 13, 2020 |
| FY2019 | Dec 31, 2017 | $328.0K | Mar 13, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $514.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $490.42M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $516.96M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $550.00M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $588.15M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $334.72M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $175.28M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $146.84M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $178.26M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $89.85M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $633.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $966.35M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $972.49M | Feb 25, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($119.15M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($475.93M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($455.53M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | ($294.60M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | ($106.99M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | ($19.26M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $38.25M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $49.24M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $83.77M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $1.58M | Mar 13, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.51B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.77B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.68B) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($1.45B) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.21B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($1.02B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($840.63M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($731.97M) | Mar 13, 2020 |
| FY2018 | Jan 1, 2018 | ($630.72M) | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | ($631.84M) | Mar 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $104.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $110.64M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $304.77M | Feb 25, 2025 |
| FY2022 | Dec 31, 2021 | $504.39M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $272.13M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $114.17M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $26.73M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $50.28M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $22.10M | Mar 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2021 | $298.14M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $122.61M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $50.00M | Mar 13, 2020 |
| FY2018 | Dec 31, 2018 | $30.00M | Mar 14, 2019 |
| FY2017 | Dec 31, 2017 | $23.00M | Mar 12, 2018 |
| FY2016 | Dec 31, 2016 | $23.00M | Feb 27, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2016 | Dec 31, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Feb 27, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2016 | Dec 31, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Feb 27, 2017 |
| FY2016 | Mar 31, 2015 | 0 | Feb 27, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 213.06M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 208.54M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 205.77M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 187.91M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 184.35M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 176.88M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 154.08M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 110.06M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 98.41M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 73.78M | Mar 12, 2018 |